The observed reduction in myocardial fibrosis and improvement in LVMI are consistent with prior studies suggesting that SGLT2 inhibitors influence myocardial structure through multiple mechanisms [22]. This evidence concerns the gene SLC5A2 and Myocardial fibrosis.